Dr. Donnellan Discusses Trials in Hematologic Malignancies

William B. Donnellan, MD
Published: Wednesday, Mar 28, 2018



William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

In acute myeloid leukemia (AML), venetoclax (Venclexta) showed a very high response rate when used in combination with a hypomethylating agent in newly-diagnosed patients. There is now a large phase III study launching, which will compare azacitidine either in combination with venetoclax or placebo. The outcome of this trial could potentially change how older patients with AML are treated.

There are several trials ongoing in myelofibrosis, such as the PAC203 study. This study is evaluating pacritinib, a JAK/FLT inhibitor, which has been shown to be effective in patients with myelofibrosis who are resistant or refractory to ruxolitinib (Jakafi). There are some concerns about toxicity, specifically cardiac and hematologic events.


William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

In acute myeloid leukemia (AML), venetoclax (Venclexta) showed a very high response rate when used in combination with a hypomethylating agent in newly-diagnosed patients. There is now a large phase III study launching, which will compare azacitidine either in combination with venetoclax or placebo. The outcome of this trial could potentially change how older patients with AML are treated.

There are several trials ongoing in myelofibrosis, such as the PAC203 study. This study is evaluating pacritinib, a JAK/FLT inhibitor, which has been shown to be effective in patients with myelofibrosis who are resistant or refractory to ruxolitinib (Jakafi). There are some concerns about toxicity, specifically cardiac and hematologic events.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x